Tirzepatide and mental side effects: what the evidence actually says

You've noticed a shift in your mood — here's what could be happening

Imagine this: three weeks into tirzepatide, you feel off. Not dramatically unwell, but quieter than usual, a little flat, maybe sleeping badly. It's easy to wonder whether the injection is to blame, or whether something else is going on entirely. Both possibilities deserve honest attention.

The NHS patient information for tirzepatide lists mood changes and sleep problems among reported side effects, though they sit in the less common category compared with nausea, reflux and digestive upset. Irritability and anxiety have also been flagged by patients in post-marketing reports, and you can read more about how tirzepatide affects mood in detail if these patterns sound familiar. None of this is a reason to panic, but it is a reason to pay attention and to keep a note of when these feelings started relative to your dose.

There is another layer worth understanding: rapid weight loss itself can affect hormones, sleep quality and energy in ways that ripple into mood. Distinguishing a medicine effect from a physiological adjustment to eating less is genuinely difficult, and a prescriber or GP is better placed than a search result to help you work that out. If something feels wrong, the answer is to raise it, not to quietly stop injecting.

For a broader look at how the body responds to this medicine, the full tirzepatide side-effect profile covers the physical and metabolic effects alongside the psychological ones.

Suicidal thoughts and self-harm: what the current evidence says

This is the question people are often too worried to type directly. Following concerns raised about GLP-1 medicines generally, regulators including the MHRA reviewed available data on whether semaglutide or tirzepatide increase the risk of suicidal thoughts or self-harm. Their conclusion, based on the clinical trial data and early post-marketing surveillance, was that there is currently no established causal link. That finding does not mean the question is closed (pharmacovigilance is ongoing) but it is the regulatory position as of mid-2026.

The Mounjaro Summary of Product Characteristics, available through the electronic Medicines Compendium, lists depression and suicidal ideation under rare but documented adverse events. Rare means fewer than one in a thousand patients in clinical reporting. It remains important because rarity does not mean impossible, and because anyone who has experienced depression or self-harm previously may be at a different baseline risk.

Our prescribers ask about mental health history as a standard part of the clinical assessment — it is not a box-ticking exercise. If you've found Mounjaro and mental health to be an area of concern, that is exactly the kind of information that shapes a prescriber's decision about whether and how to proceed.

When you need medical help, and what to do right now

Some signs should not wait for your next scheduled review. Get help promptly if you experience:

• Thoughts of self-harm or suicide, or feeling that life is not worth living
• A sudden and significant low mood that comes on quickly or intensifies
• Severe agitation, paranoia, or confusion that feels out of character
• Any mental health symptom that worries you, even if you're not sure it's related to the medicine

In an emergency, call 999 or go to your nearest A&E. For urgent but non-emergency support, NHS 111 is available 24 hours a day. The Samaritans can be reached any time on 116 123. Your GP is the right person to speak to about whether to pause or adjust treatment.

If you believe tirzepatide has contributed to a mental health symptom, reporting it through the Yellow Card scheme helps the MHRA build a clearer picture of what is happening in real-world use. You don't need to be certain a medicine caused something to report it, a reasonable suspicion is enough, and your report genuinely matters for future patients.

Our prescribers are available seven days a week through aftercare if you have concerns between reviews. You can also reach the team directly via our contact page.

How the consultation addresses mental side effects before you start

You might be reading this because you're still deciding. That's a good position to be in. The clinical assessment that happens before any treatment is prescribed is precisely where this conversation belongs. A prescriber will ask about your mental health history, any current medications (some interact with the appetite-suppression effects in ways that affect mood and energy), and any periods of depression or anxiety in the past, all of which are covered in our guide to Mounjaro's mental side effects.

It is worth being direct. Patients who share the full picture tend to get better-tailored care. If a prescriber decides tirzepatide is not right for you given your history, that is a clinical judgement in your favour, not a door slamming. There may be an alternative, a different starting point, or simply a plan that includes closer monitoring. Our page on side effects from tirzepatide sets out what to expect across the full course of treatment, which can help you have a more informed conversation with your prescriber. If you'd also like a focused summary before your consultation, our overview of Mounjaro side effects brings together the most clinically relevant information in one place.

If you'd like to explore treatment through a clinician-led service with same-day review by a GPhC-registered prescriber, you can start the process through our free consultation. Our clinical team's approach to prescribing (including how mental health history is factored in) is described further on our clinical team page.